Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics.
A short review of the metabolism of psychoactive drugs and the pharmacogenetic factors regulating the enzymes involved is presented here. The potential clinical usefulness of phenotyping and genotyping individuals, with regard to their drug metabolic capacity, is discussed. Indications for genotyping CYP2D6 and a flow scheme for the combined use of conventional therapeutic drug monitoring (TDM) and pharmacogenetic methods for optimizing dosage-schedules of psychoactive drugs are suggested.
Dahl
M L
ML
Department of Medical Laboratory Sciences & Technology, Huddinge University Hospital, Sweden.
Sjöqvist
F
F
D000928:Antidepressive Agents / Q000097:blood / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000097:blood / Q000627:therapeutic use*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D016903:Drug Monitoring / Q000379:methods*; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics; D010641:Phenotype
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D003577:Cytochrome P-450 Enzyme System